Multidimensional liquid chromatography platform for profiling alterations of clusterin N-glycosylation in the plasma of patients with renal cell carcinoma

Fateme Tousi, Jonathan Bones, Othon Iliopoulos, William S. Hancock, Marina Hincapie*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    20 Citations (Scopus)

    Abstract

    Identification of potential changes in the glycosylation of existing cancer biomarkers can result in a higher level of diagnostic sensitivity and specificity. Clusterin (Apolipoprotein J) has been implicated in renal cell carcinoma (RCC) and other types of malignancy as potential biomarker. In the present work, an automated multi-dimensional HPLC platform enabling high throughput affinity enrichment of clusterin from plasma samples was developed. Integrated with two dimensional gel electrophoresis, high purity clusterin in microgram quantities suitable for glycan characterization was isolated. The analytical platform was applied to study clusterin glycosylation in a small group of RCC patients before and after nephrectopy as a pilot study to evaluate the performance of the platform. A statistically significant decrease was observed in the levels of a bi-antennary digalactosyl disialylated (A2G2S(3)2) glycans while the levels of a core fucosylated bi-antennary digalactosyl disialylated glycan (FA2G2S(6)2) and a tri-antennary trigalactosyl disialylated glycan (A3G3S(6)2) were increased in the post-surgery plasma samples.

    Original languageEnglish
    Pages (from-to)121-128
    Number of pages8
    JournalJournal of Chromatography A
    Volume1256
    DOIs
    Publication statusPublished - 21 Sep 2012

    Keywords

    • Clusterin
    • Multi-dimensional HPLC
    • N-glycan
    • Renal cell carcinoma
    • Two dimensional gel electrophoresis (2-DE)
    • UPLC-HILIC

    Fingerprint

    Dive into the research topics of 'Multidimensional liquid chromatography platform for profiling alterations of clusterin N-glycosylation in the plasma of patients with renal cell carcinoma'. Together they form a unique fingerprint.

    Cite this